UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites

Biomedicine & pharmacotherapy, 2023-09, Vol.165, p.115116-115116, Article 115116

2023

Volltextzugriff (PDF)

Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205

Journal of pharmacology & pharmacotherapeutics, 2023-03, Vol.14 (1), p.54-61

2023

Volltextzugriff (PDF)

OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis

Current research in pharmacology and drug discovery, 2023-01, Vol.5, p.100163-100163, Article 100163

2023

Volltextzugriff (PDF)

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes

Clinical and translational science, 2022-06, Vol.15 (6), p.1449-1459

2022

Volltextzugriff (PDF)

Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study

The International Journal of Cardiovascular Imaging, 2014-06, Vol.30 (5), p.979-989

2014

Volltextzugriff (PDF)

Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial

Clinical gastroenterology and hepatology, 2021-12, Vol.19 (12), p.2626-2635.e7

2021

Volltextzugriff (PDF)

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

Clinical drug investigation, 2023-09, Vol.43 (9), p.709-717

2023

Volltextzugriff (PDF)

OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension

Journal of experimental pharmacology, 2023-07, Vol.15, p.279-290

2023

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia

Hepatology (Baltimore, Md.), 2018-03, Vol.67 (3), p.1003-1013

2018

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Journal of nuclear cardiology, 2012-08, Vol.19 (4), p.681-692

2012

Volltextzugriff (PDF)

Industry perspective on the medical risk of visible particles in injectable drug products

PDA journal of pharmaceutical science and technology, 2015-01, Vol.69 (1), p.123-139

2015

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

Journal of nuclear cardiology, 2012-04, Vol.19 (2), p.319-329

2012

Volltextzugriff (PDF)

Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction

European urology, 2001-05, Vol.39 (5), p.558-564

2001

Volltextzugriff (PDF)

Finding unrecognized information in overactive bladder clinical trial data: A new approach to understanding placebo and treatment effects

Neurourology and urodynamics, 2013-04, Vol.32 (4), p.308-313

2013

Volltextzugriff (PDF)

Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Commentary

European urology, 2001, Vol.39 (5), p.558-564

2001

Volltextzugriff (PDF)

Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media

The Pediatric infectious disease journal, 2004-09, Vol.23 (9), p.834-838

2004

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites

Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205

OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes

Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study

Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension

Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Industry perspective on the medical risk of visible particles in injectable drug products

A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction

Finding unrecognized information in overactive bladder clinical trial data: A new approach to understanding placebo and treatment effects

Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Commentary

Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media

Suchergebnisse filtern